Collective years investing in healthcare
Working with MVM
MVM partners with best-in-class management teams to bring innovative products to market, drive growth, make strategic acquisitions, and establish new standards of care in medicine.
We seek out portfolio companies that address significant unmet needs in large addressable markets. These include medical conditions for which there is no adequate treatment, therapies for which existing technologies are too expensive, or diseases for which there is no accurate diagnostic capability, among other situations.
In all of these cases, we prioritize businesses that have a clearly differentiated technology with durable protection against competition, whether through intellectual property, barriers to market entry, statutory exclusivity, or unique branding. After investment, we work closely with management teams to help the business achieve both its near and long term goals.
While MVM does not use fixed investment criteria, we focus on companies that fit the following profile.
We provide growth equity to commercial-stage businesses. In other words, our investments are intended to accelerate the growth and scale of companies that have commercially available products.
We invest broadly across healthcare and life sciences. We have made investments in medical devices, pharmaceuticals, diagnostics, digital health, health IT, life science tools, contract research, and contract manufacturing, among other areas. We focus on identifying differentiated products or technologies in each of these categories.
We expect to make aggregate investments of $20 to 100 million in each of our portfolio companies over the life of our holding. In select circumstances, we have the capacity to make larger investments to support unique or creative financing opportunities.
MVM invests in innovative healthcare companies. Our active portfolio companies are transforming the delivery of healthcare by enabling higher quality, cost-effective care in large, global markets. We maintain a concentrated portfolio, focused on building world-class companies.
MVM has extensive experience guiding our portfolio companies to successful exits, including both acquisitions and initial public offerings. Selected former portfolio companies include:
VitalConnect Secures over $30 Million in Oversubscribed Series F Financing
July 18, 2023
SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed […]
CurvaFix Closes $39 Million Series C Financing Round Led by MVM Partners and Announces CEO Transition
July 14, 2023
BELLEVUE, Wash.–(BUSINESS WIRE)–CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the close of […]
Vertos Medical Secures $26 Million to Expand Commercialization Efforts and Develop Breakthrough Treatments for Chronic Low Back Pain
June 7, 2023
ALISO VIEJO, Calif., June 7, 2023 /PRNewswire/ — Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for […]
eXmoor pharma completes $35 million Series A to expand cell and gene therapy manufacturing capabilities
May 30, 2023
New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK, May […]
GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing
March 23, 2023
TEMPE, Ariz., March 23, 2023 /PRNewswire/ — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients […]
OSSIO Launches World’s First and Only Non-Permanent Compression Staple
February 7, 2023
OSSIOfiber® Compression Staple Answers Surgeon, Patient Demand in Fastest Growing Product Category in Extremities WOBURN, Mass.–(BUSINESS WIRE)–OSSIO, Inc., a fast-growing orthopedic fixation […]
VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite
February 6, 2023
Second Generation GENOSYL® DS is the first and only Inhaled Nitric Oxide delivery system that is FDA-approved for rebreathing anesthesia, […]
VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System
January 9, 2023
VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced […]
MVM Closes Oversubscribed Fund at $500 Million Hard Cap
November 14, 2022
BOSTON & LONDON — MVM Partners is pleased to announce the closing of its sixth healthcare fund, MVM VI, with […]
Old City Hall, 45 School Street
Boston MA 02108
30 St George Street
London W1S 2FH